Kymera Therapeutics, Inc. (KYMR) AI Stock Analysis

Kymera Therapeutics, Inc. is a biopharmaceutical company specializing in the discovery and development of small molecule therapeutics that selectively degrade disease-causing proteins by leveraging the body's natural protein degradation system. Headquartered in Watertown, Massachusetts, the company advances multiple pipeline programs. Its IRAK4 program is in Phase I clinical trials for immunology-inflammation diseases like hidradenitis suppurativa, atopic dermatitis, rheumatoid arthritis, macrophage activation syndrome, and general pustular psoriasis. Additional pipeline assets include IRAKIMiD for MYD88-mutated diffuse large B cell lymphoma, STAT3 for hematologic malignancies, solid tumors, autoimmune diseases, and fibrosis, and MDM2 for hematological malignancies and solid tumors.

Kymera's financial results reflect high research spending and fluctuating collaboration revenues. Annual revenue decreased from $72.8M in FY2021 to $46.8M in FY2022, rose to $78.6M in FY2023, and fell to $47.1M in FY2024 and $39.2M in FY2025. Across the 5 years from FY2020 to FY2025, revenue achieved a 2.9% CAGR. Net income widened from -$100.2M in FY2021 to -$311.4M in FY2025 as R&D expense expanded to $316.6M. Operating margin in FY2025 was -891.3%, and EPS was -$3.68. For the latest quarter ended June 30, 2026, revenue increased 466.4% year-over-year, bringing trailing twelve months revenue to $105.0M with an EPS of -$3.25.

As of June 30, 2026, Kymera reported $691.0M in cash and short-term investments against $82.2M in total debt, yielding a net cash position of $608.8M. The company maintains solid liquidity with a current ratio of 9.83 and a debt-to-equity ratio of 0.05 on shareholders' equity of $1.51B. Cash flow operations remained negative in FY2025, with operating cash flow at -$232.9M and free cash flow at -$234.3M, which included capital expenditures of $1.4M. Over the trailing 5-year period, share count changed by 91.0%.

Kymera trades at a price-to-sales multiple of 82.1x and an enterprise value to revenue multiple of 85.6x, compared to the median of its US-listed Healthcare peers at 4.1x price-to-sales. Its price-to-book ratio is 6.4x, supported by a market capitalization of $8.62B and an enterprise value of $8.98B. The stock delivered a 1-year return of 73.3%, outperforming the S&P 500 (SPY) return of 16.8%. Over a 5-year horizon, Kymera's return of 83.2% closely tracked the S&P 500 (SPY) return of 83.0%.

Wall Street sentiment includes 17 Strong Buy, 5 Buy, and 2 Hold ratings, with no Sell or Strong Sell ratings. The mean price target is $139.35, representing a 33.0% upside compared to the last close of $104.78. For the current fiscal year ending December 31, 2026, analysts estimate revenue of $104.8M and an EPS of -$3.85. For the next fiscal year, 21 analysts estimate revenue of $40.7M and an EPS of -$5.10. Kymera beat EPS estimates in 2 of the last 4 quarters, with next earnings scheduled for November 3, 2026.

This page is an AI-written research summary of Kymera Therapeutics, Inc. (KYMR). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: KYMR income statement, KYMR balance sheet, KYMR key metrics, KYMR analyst forecast, KYMR chart. See the KYMR stock overview for the latest quote and news.